| 28.38 5.99 (26.75%) | 09-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.97 |
1-year : | 42.01 |
| Resists | First : | 30.79 |
Second : | 35.97 |
| Pivot price | 25.01 |
|||
| Supports | First : | 25.33 |
Second : | 21.95 |
| MAs | MA(5) : | 24.12 |
MA(20) : | 25.89  |
| MA(100) : | 26.95 |
MA(250) : | 33.04 |
|
| MACD | MACD : | -1 |
Signal : | -1 |
| %K %D | K(14,3) : | 34 |
D(3) : | 14.9 |
| RSI | RSI(14): 59.9 |
|||
| 52-week | High : | 53.65 | Low : | 21.95 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MAZE ] has closed Bollinger Bands are 37.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.47 - 29.66 | 29.66 - 29.84 |
| Low: | 24.09 - 24.3 | 24.3 - 24.49 |
| Close: | 28.01 - 28.39 | 28.39 - 28.73 |
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Fri, 18 Sep 2026
Maze Therapeutics stock hits 52-week low at 22.44 USD By Investing.com - Investing.com Nigeria
Fri, 18 Sep 2026
Maze Therapeutics stock hits 52-week low at 22.44 USD - Investing.com
Fri, 18 Sep 2026
Maze Therapeutics, Inc. (MAZE) Stock Analysis: A 166.83% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Wed, 16 Sep 2026
Maze Therapeutics (MAZE) Slips 1.30% to $23.91 as Shares Drift Toward Key Support - Runaway Gap - careplusvn.com
Fri, 11 Sep 2026
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - The Motley Fool
Fri, 04 Sep 2026
Maze Therapeutics (NASDAQ: MAZE) officer lines up new stock sale after recent 10b5-1 trades - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 106.7 (%) |
| Shares Short | 5,990 (K) |
| Shares Short P.Month | 5,530 (K) |
| EPS | -2.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.15 |
| Profit Margin | 0 % |
| Operating Margin | -728.1 % |
| Return on Assets (ttm) | -21.8 % |
| Return on Equity (ttm) | -37.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.36 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | -2.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -107 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | -11.64 |
| PEG Ratio | 0 |
| Price to Book value | 3.47 |
| Price to Sales | 78.82 |
| Price to Cash Flow | -14.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|